Phase II, multicenter trial, exploring 'chemosparing' strategy associating Obinutuzumab vertical bar Ibrutinib followed by an MRD driven strategy, in previously untreated symptomatic medically fit Chronic Lymphocytic Leukemia patients (CLL): preliminary results